Navigation Links
Cancer drug effectively treats transplant rejections
Date:12/26/2008

CINCINNATIUniversity of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.

Results of the study are published in the Dec. 27, 2008, edition of the journal Transplantation.

Steve Woodle, MD, and colleagues found that a cancer drugbortezomibused to treat multiple myeloma, or cancer of the plasma cells, is effective in treating rejection episodes caused by antibodies that target transplanted kidneys and reversing rejection episodes that did not respond to standard therapies.

B-lymphocytes, or B cells, play a large role in the humoral immune response by making immune proteins that attack transplanted organs.

"We found a body of literature demonstrating that bortezomib works well in suppressing transplant rejection in the laboratory," says Woodle, lead author of the study and chief of transplant surgery at UC. "Moreover, it worked well in models of autoimmune diseases."

T-lymphocytes, or T cells, are white blood cells that were commonly thought to cause the rejection of transplanted organs.

Woodle and his team began searching for agents that targeted plasma cells in 2005.

"It has become clear that plasma cells and the antibodies they produce play a bigger role in rejection than previously thought, and the development of therapies targeting these cells has lagged," he says. "We realized that current therapies don't target the plasma cells which may produce the antibody, in general."

Researchers administered this drug to six kidney transplant recipients with treatment-resistant organ rejection, evaluating and recording their responses to the treatment.

In each case, treatment with the drug provided prompt rejection reversal, prolonged reductions in antibody levels and improved organ function with suppression of recurrent rejection for at least five months.

Jason Everly, a board-certified oncology pharmacist in the division of transplant surgery at UC and co-author of the study, says the toxicities associated with this drug were predictable and manageable and were much less than those associated with other anti-cancer agents.

"We are pleased to see its toxicities are similar in transplant recipients suffering from treatment-resistant mixed organ rejection," he adds. "We hope it will be a viable therapeutic treatment option in this patient group."

Woodle says although this data is promising, it is difficult to overestimate the implications of this drug.

"We have an immunosuppressive agent that for the first time can target antibody-producing plasma cells with an efficacy similar to drugs that target T cells," he says. "This has significant implications for transplantation and auto immune disease."

UC researchers are currently conducting four industry-supported clinical trials to expand these findings.


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati
Source:Eurekalert

Related medicine news :

1. A new light on tumor immunotherapy for gastric cancer
2. Cancer Medicine Advances on Many Fronts
3. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
4. E. coli engineered to produce important class of antibiotic, anti-cancer drugs
5. Gene Variant Tied to Smokers Risk of Lung Cancer
6. Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials'
7. Holiday Online Auction - Dedicated to Awareness of Male Breast Cancer - Hosted by John W. Nick Foundation, Inc. at MaleBreastCancer.org
8. Mutations common to cancer and developmental disorder examined in a novel disease model
9. SNPs of ABC transporter genes linked to lung cancer risk
10. Gene Boosts Drinkers Colon Cancer Risk
11. Groundbreaking, inexpensive, pocket-sized ultrasound device can help treat cancer, relieve arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , ... March 01, 2017 , ... After a long ... a spring cleanse. While juice cleanses and workouts top the detox categories, there is ... or physical regime. The Kerry Gaynor Method’s Vital Lung Detox is an herbal-based formula ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... PurThread’s permanently embedded anti-odor solution to cotton knit and woven fabrics. , ... while maintaining the luxurious look and feel of cotton. Cotton Incorporated has ...
(Date:3/1/2017)... ... , ... Award-winning medical group Allied Anesthesia today announced that, as of 2016, ... more than one trip per year since 1998. Char was named the Los Angeles ... details of his charitable work. Char has been an Allied Anesthesiologist since 2000. , ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... announced special pricing in the month of March for treatments aimed at tightening ... special features use on Thermage skin tightening, with 30 percent off all Thermage ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... “Letter of ... of published author, Maria Teresa Hamilton, survivor of the Civil War in El Salvador, ... Christian at the age of fifteen. I dedicated myself to serve in very poor ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 28, 2017 Persistence Market Research in ... Debridement Product Market 2016-2024," offers insights into developments ... North America that are significantly ... the overall market performance has been taken into ... focuses on developing different products to retain market ...
(Date:2/28/2017)... , Feb. 28, 2017 The global gynecology ... by 2021 from USD 1.73 billion in 2016, at a ... ... report: http://www.reportlinker.com/p04734938-summary/view-report.html Major factors contributing to the ... gynecological diseases, increasing awareness on gynecological diseases, and rising government ...
(Date:2/28/2017)... Summary ... This report provides all the information you require ... activities since 2010. Read the full report: http://www.reportlinker.com/p03605620-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
Breaking Medicine Technology: